Nateglinide 60 mg (Generic)

Product Overview

Nateglinide 60 mg is a generic oral antihyperglycemic medication indicated for the management of type 2 diabetes mellitus. Produced by Glenmark Pharmaceuticals Ltd., each strip contains ten tablets of 60 mg nateglinide. Packs are available in 60, 90, and 120‑tablet quantities to suit individualized therapy. The drug belongs to the meglitinide class, which enhances insulin secretion from pancreatic beta‑cells in a glucose‑dependent manner, providing a rapid but short‑acting effect that can be combined with other oral agents or insulin for tighter glycemic control.

What is Nateglinide 60 mg (Generic)

Nateglinide 60 mg (generic) refers to the active ingredient supplied at a strength of sixty milligrams per tablet. The formulation is manufactured by Glenmark Pharmaceuticals Ltd., a company with a broad portfolio in diabetes care. It is classified as a meglitinide antidiabetic and is used specifically for type 2 diabetes. Pharmacodynamically, nateglinide acts quickly, reaching peak plasma concentrations within one to two hours, and has a short half‑life of about one hour, making it suitable for administration before meals.

Uses and Benefits

The primary use of nateglinide 60 mg is to lower post‑prandial glucose excursions in adults with type 2 diabetes who have not achieved adequate control through diet and exercise alone. Clinical data show that taking the tablet before each main meal can reduce post‑meal glucose spikes by up to 30 percent. Benefits include modest reductions in HbA1c, improved fasting glucose, and a relatively low risk of hypoglycemia when used as monotherapy. When combined with other antidiabetic agents, dose adjustments are recommended to maintain safety.

How It Works

Nateglinide binds to the sulfonyl‑leucine receptor on pancreatic beta‑cells, closing ATP‑sensitive potassium channels and prompting insulin release only when blood glucose rises. This glucose‑dependent mechanism mirrors the normal physiological insulin response to meals, resulting in a rapid increase in insulin that peaks within a few hours and then declines. Unlike sulfonylureas, nateglinide does not stimulate insulin secretion at low glucose levels, which contributes to its favorable hypoglycemia profile when used alone.

Dosage Guidelines

The recommended initial dose is one 60‑mg tablet taken orally before each main meal, typically three times daily. Dose titration may be performed based on individual glycemic response, with a maximum daily dose of 180 mg (three tablets) when used as monotherapy. When co‑administered with other glucose‑lowering medications such as metformin or sulfonylureas, the nateglinide dose should be reduced to minimize hypoglycemia risk. Patients should be instructed to skip the dose if a meal is missed and to monitor blood glucose regularly to fine‑tune therapy.

Side Effects

Most adverse events associated with nateglinide 60 mg are mild and include hypoglycemia, headache, nasopharyngitis, and upper respiratory infections. Less common but serious effects can involve pancreatitis, severe hypoglycemia, and elevations in liver enzymes. Patients should be advised to recognize symptoms of low blood sugar—such as sweating, tremor, or confusion—and treat them promptly with fast‑acting carbohydrates. If hypersensitivity reactions such as rash or swelling occur, medical attention should be sought immediately.

Warnings and Precautions

Before initiating therapy, assess renal and hepatic function, as well as concomitant medications that may increase hypoglycemia risk. Nateglinide is contraindicated in patients with known hypersensitivity to the drug or its excipients. Caution is advised in hepatic impairment, and dose adjustments may be necessary. Pregnant or lactating women should only use the medication if the benefits outweigh potential risks, and healthcare providers should discuss alternatives. Regular follow‑up visits are recommended to evaluate glycemic control, organ function, and overall treatment safety.

Frequently Asked Questions

1. What is the purpose of nateglinide 60 mg?

Nateglinide 60 mg is used to lower post‑prandial blood glucose levels in adults with type 2 diabetes. It works by stimulating insulin release only when glucose rises after meals, helping to prevent spikes and improve overall glycemic control.

2. How should I take nateglinide 60 mg?

Take one tablet before each main meal, usually three times daily. If you skip a meal, skip the corresponding dose. Do not take the medication if your blood glucose is low; treat the hypoglycemia first and then reassess dosing.

3. Can nateglinide cause low blood sugar?

Yes, nateglinide can lower blood glucose and may cause hypoglycemia, especially when combined with other glucose‑lowering drugs such as sulfonylureas or insulin. Signs include sweating, shakiness, confusion, or dizziness. Treat low blood sugar promptly with fast‑acting carbohydrates and monitor levels.

4. Are there any serious side effects I should watch for?

Serious adverse events are rare but can include pancreatitis, severe hypoglycemia, and liver enzyme abnormalities. Seek immediate medical attention if you experience persistent abdominal pain, severe nausea, or signs of an allergic reaction such as rash or swelling.

5. Where can I find more information about nateglinide?

Detailed prescribing information and safety data are available from authoritative sources such as the U.S. Food and Drug Administration, MedlinePlus, and the National Institutes of Health. These resources provide comprehensive guidance for both patients and clinicians.

Related Products

• Tazret Gel 0.05% (Tazarotene)
• Tazret Forte Cream (Tazarotene)
• Apremilast 30 mg (Generic)
• Aprezo 30 mg (Apremilast)
• Tazarotene Gel 0.05% (Generic)
• Tazarotene Cream (Generic)
• Flucort Cream (Fluocinolone)
• Flucort Cream 20gm (Fluocinolone)
• Flucort N Cream (Fluocinolone/Neomycin)
• Flucort C Cream (Fluocinolone/Ciclopirox)
• Flucort H Cream (Fluocinolone)
• Halovate Cream (Halobetasol)